Becton, Dickinson and Company $BDX Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 78.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 89,366 shares of the medical instruments supplier’s stock after selling 319,673 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Becton, Dickinson and Company were worth $15,394,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 0.8% during the first quarter. Victory Capital Management Inc. now owns 110,860 shares of the medical instruments supplier’s stock valued at $25,394,000 after purchasing an additional 826 shares during the last quarter. Kestra Private Wealth Services LLC raised its position in shares of Becton, Dickinson and Company by 7.2% during the 1st quarter. Kestra Private Wealth Services LLC now owns 5,700 shares of the medical instruments supplier’s stock worth $1,306,000 after purchasing an additional 381 shares during the period. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Becton, Dickinson and Company by 3.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 22,339 shares of the medical instruments supplier’s stock worth $5,117,000 after purchasing an additional 810 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its position in Becton, Dickinson and Company by 7.8% during the 1st quarter. Lindbrook Capital LLC now owns 992 shares of the medical instruments supplier’s stock valued at $227,000 after purchasing an additional 72 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BDX shares. Jefferies Financial Group cut their target price on Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday, November 7th. Piper Sandler cut their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus cut their price target on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $203.27.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,249 shares of company stock valued at $231,358. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.7%

BDX stock opened at $192.26 on Wednesday. The firm’s 50-day moving average is $186.68 and its two-hundred day moving average is $181.91. The company has a market capitalization of $55.11 billion, a price-to-earnings ratio of 34.58, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.